Phil Patten
About Phil Patten
Phil Patten Chief Scientific Officer at Initial Therapeutics
Phil Patten is the Chief Scientific Officer of Initial Therapeutics, a portfolio company of ATP. In this role, he leverages his extensive background in biological sciences and chemistry to steer the scientific vision and strategy of the company. His leadership helps to advance Initial Therapeutics' mission to discover and develop groundbreaking treatments.
Phil Patten Educational Background
Phil Patten earned his Bachelor of Science in Biology from the California Institute of Technology, a foundation that set the stage for his distinguished career in the scientific field. He furthered his education by completing a PhD in Biological Sciences from Stanford University. Following that, he completed postdoctoral studies in Chemistry at the University of California, Berkeley, refining his expertise in both biology and chemistry.
Phil Patten Role in DiCE Therapeutics
Phil Patten was a founder and the Chief Scientific Officer of DiCE Therapeutics, a publicly traded biotechnology company. His innovative work in this role contributed significantly to the company's development and market presence. DiCE Therapeutics is recognized for its breakthroughs in biotechnology, largely thanks to Patten's scientific leadership and vision.
Phil Patten Professional Experience in Biotechnology
Phil Patten began his industrial career at Maxygen, where he applied directed evolution to therapeutic proteins. His work at Pioneer Hi-Bred as a DuPont Fellow involved managing teams focused on utilizing directed evolution and synthetic biology in agriculture. As the Senior Vice President of Biology at Achaogen, he led a team that discovered the first clinical stage small molecule inhibitor of LpxC, highlighting his expertise in drug discovery and development.
Phil Patten Patents and Advisory Roles
Phil Patten holds more than 90 granted US patents, showcasing his prolific contributions to scientific innovation. He has served on multiple scientific advisory boards, providing expert guidance and insight. Furthermore, he was a member of the Biology and Bioengineering Chair’s Council at the California Institute of Technology from 2018 to 2020, underlining his commitment to advancing the field of biological sciences.